What's in RemeGen Co., Ltd.'s pipeline?

RemeGen Co., Ltd. has 29 drugs in our index: 2 marketed, 0 filed, 7 in Phase 3, 15 in Phase 2, 5 in Phase 1.

Which companies overlap with RemeGen Co., Ltd.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., Merck Sharp & Dohme LLC, Sanofi.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/remegen-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

RemeGen Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RemeGen Co., Ltd. pipeline: 2 marketed, 0 filed, 7 Phase 3, 15 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 7 Phase 3 15 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Placebo plus standard therapy	Placebo plus standard therapy	marketed
Telitacicept Freeze-dried powder Injection 80mg	Telitacicept Freeze-dried powder Injection 80mg	marketed
RC-28E	RC-28E	phase 3	PD-1 inhibitor	PD-1	Oncology
Tislelizumab plus Carboplatin and Paclitaxel	Tislelizumab plus Carboplatin and Paclitaxel	phase 3	PD-1 inhibitor and chemotherapeutic agents	PD-1	Oncology
RC148 plus Carboplatin and Paclitaxel	RC148 plus Carboplatin and Paclitaxel	phase 3	PD-L1 inhibitor	PD-L1	Oncology
Pertuzumab Injection	Pertuzumab Injection	phase 3	HER2 inhibitor monoclonal antibody	HER2 (Human Epidermal Growth Factor Receptor 2)	Oncology
Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine	Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine	phase 3	Combination therapy: antibody-drug conjugate, PD-1 inhibitor, platinum agent, and antimetabolite	HER2, PD-1, DNA (via oxaliplatin and capecitabine)	Oncology
RC48-ADC	RC48-ADC	phase 3	HER2-targeted antibody-drug conjugate	HER2 (human epidermal growth factor receptor 2)	Oncology
RC28-E	RC28-E	phase 3	PD-1 inhibitor	PD-1	Oncology

Therapeutic area mix

Oncology · 11

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 4 shared drug classes
Shanghai Henlius Biotech · 3 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 3 shared drug classes
Merck Sharp & Dohme LLC · 3 shared drug classes
Sanofi · 3 shared drug classes
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · 2 shared drug classes
Bristol-Myers Squibb · 2 shared drug classes
Celltrion · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for RemeGen Co., Ltd.:

Cite this brief

Drug Landscape (2026). RemeGen Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/remegen-co-ltd. Accessed 2026-06-10.